%0 Generic
%A Rybakowska, P.
%A van Gassen, S.
%A Perez-Sanchez, C.
%A Ibanez-Costa, A.
%A Varela, N.
%A Castro, R. Ortega
%A Fernandez-Roldan, C.
%A Jimenez-Moleon, I.
%A Ortego, N.
%A Raya, E.
%A Quesada, R. Aguilar
%A Lopez-Pedrera, C.
%A Estevez, E. Collantes
%A Saeys, Y.
%A Alarcon-Riquelme, M.
%A Maranon, C.
%T MASS CYTOMETRY DATA RECLASSIFY SYSTEMIC AUTOIMMUNE DISEASE PATIENTS IN PHENOTYPICALLY DISTINCTIVE GROUPS
%D 2022
%@ 0003-4967
%U http://hdl.handle.net/10668/20061
%X Systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), systemic sclerosis (SSC), Sjögren’s syndrome (SJS), mixed connective tissue disease (MCTD), primary antiphospholipid syndrome (PAPS) and undifferentiated connective tissue disease (UCTD) are classified as systemic autoimmune diseases (SADs). They are diagnosed based on different clinical and laboratory criteria. Due to their high internal heterogeneity and overlapping symptoms, SADs are difficult to diagnose. Therefore, molecular and cellular-based studies need to be undertaken to precisely classify the patients. Mass cytometry is a single-cell proteomics technology that measures  approximately 50 markers per cell, thus it is a suitable tool to perform deep-phenotyping studies in SADs.
%K Antiphospholipid syndrome
%K Mixed connective tissue disease
%K Undifferentiated connective tissue diseases
%K Proteomics
%~